Astellas Pharma Global Development, Inc.
Clinical trials sponsored by Astellas Pharma Global Development, Inc., explained in plain language.
A global pharmaceutical company developing medicines, a subsidiary of Astellas Pharma.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Radioactive tracer tracks a new cancer Drug's path through the body Results expected Oct 2026 (estimated)
- Can a smart drug home in on Hard-to-Treat cancers? Results expected Dec 2026 (estimated)
- New drug safety check for advanced bladder cancer in india Results expected Dec 2026 (estimated)
- Can a menopause drug cool hot flashes in prostate cancer patients? Results expected Apr 2027 (estimated)
- New cancer drug interaction study recruits healthy volunteers Results expected May 2027 (estimated)
-
Targeted antibody zolbetuximab tested with chemo against advanced stomach cancer
Disease control Not yet recruitingResearchers are testing whether adding zolbetuximab to standard chemotherapy is safe and helps control advanced stomach or gastroesophageal junction cancer in Indian patients. The trial enrolls 50 adults whose tumors carry the Claudin 18.2 protein but not HER2. Participants recei…
Phase 4 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Sep 21, 2026 18:00 UTC
-
Can a menopause drug cool hot flashes in prostate cancer patients?
Disease control Not yet recruitingThis study looks at whether a drug called fezolinetant, used for hot flashes, is processed differently in men with prostate cancer who are taking hormone therapy. It compares blood levels of fezolinetant in men on different hormone drugs (enzalutamide, apalutamide, or bicalutamid…
Phase 1 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Radioactive tracer tracks a new cancer Drug's path through the body
Knowledge-focused Not yet recruitingThis early-stage trial is investigating how the body absorbs, breaks down, and eliminates setidegrasib, an experimental drug being developed for certain cancers. To trace its journey, the drug is tagged with a low-dose radioactive marker, similar to the radiation from an X-ray. H…
Phase 1 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Knowledge-focused
Last updated Aug 21, 2026 00:00 UTC